An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
TriLink BioTechnologies, a Maravai LifeSciences company, has entered into a non-exclusive License and Supply Agreement with Lonza for its CleanCap mRNA capping technology. This agreement will allow Lonza to use TriLink's patented cap analogs for mRNA development and manufacturing services, enhancing the accessibility of CleanCap technology in the industry. CleanCap technology offers high capping efficiency and streamlines mRNA production processes, contributing to improved mRNA function and increased capped material yield.
TriLink BioTechnologies, una società di Maravai LifeSciences, ha stipulato un contratto di licenza e fornitura non esclusivo con Lonza per la sua tecnologia di capping mRNA CleanCap. Questo accordo permetterà a Lonza di utilizzare gli analoghi di cappuccio brevettati di TriLink per lo sviluppo e la produzione di mRNA, aumentando l'accessibilità della tecnologia CleanCap nel settore. La tecnologia CleanCap offre un'alta efficienza di capping e semplifica i processi di produzione di mRNA, contribuendo a migliorare la funzione dell'mRNA e ad aumentare la resa del materiale cappato.
TriLink BioTechnologies, una compañía de Maravai LifeSciences, ha firmado un Acuerdo de Licencia y Suministro no exclusivo con Lonza para su tecnología de encapsulación de mRNA CleanCap. Este acuerdo permitirá a Lonza usar los análogos de tapa patentados de TriLink para el desarrollo y servicios de fabricación de mRNA, mejorando la accesibilidad de la tecnología CleanCap en la industria. La tecnología CleanCap ofrece una alta eficiencia de capsulación y simplifica los procesos de producción de mRNA, contribuyendo a mejorar la función del mRNA y aumentar el rendimiento del material encapsulado.
마라바이 라이프사이언스의 자회사인 트릴링크 바이오테크놀로지는 클린캡 mRNA 캡핑 기술에 대한 비독점 라이선스 및 공급 계약을 론자와 체결했습니다. 이 계약은 론자가 mRNA 개발 및 제조 서비스를 위해 트릴링크의 특허 받은 캡 아날로그를 사용할 수 있게 하여 산업 내 클린캡 기술의 접근성을 높입니다. 클린캡 기술은 높은 캡핑 효율을 제공하고 mRNA 생산 과정을 간소화하여 mRNA 기능을 향상시키고 캡 처리된 재료의 수율을 증가시킵니다.
TriLink BioTechnologies, une entreprise de Maravai LifeSciences, a conclu un accord de licence et d'approvisionnement non exclusif avec Lonza pour sa technologie de coiffage d'mRNA CleanCap. Cet accord permettra à Lonza d'utiliser les analogues de bouchon brevetés de TriLink pour le développement et les services de fabrication d'mRNA, améliorant l'accessibilité de la technologie CleanCap dans l'industrie. La technologie CleanCap offre une haute efficacité de coiffage et simplifie les processus de production d'mRNA, contribuant à améliorer la fonction de l'mRNA et à augmenter le rendement du matériel coiffé.
TriLink BioTechnologies, ein Unternehmen von Maravai LifeSciences, hat eine nicht-exklusive Lizenz- und Liefervereinbarung mit Lonza für seine CleanCap mRNA-Capping-Technologie abgeschlossen. Diese Vereinbarung ermöglicht es Lonza, die patentierten Kap-Analoga von TriLink für die mRNA-Entwicklung und -Herstellungsdienste zu nutzen und verbessert den Zugang zur CleanCap-Technologie in der Branche. Die CleanCap-Technologie bietet eine hohe Capping-Effizienz und vereinfacht die mRNA-Produktionsprozesse, was zu einer verbesserten Funktion der mRNA und einer erhöhten Ausbeute an gecapptem Material beiträgt.
Positive
TriLink BioTechnologies has expanded access to its CleanCap mRNA capping technology through the agreement with Lonza, potentially leading to increased adoption and utilization of CleanCap technology in the industry.
CleanCap technology has shown to enhance mRNA function, streamline manufacturing processes, and maximize capped material yield, indicating potential efficiency improvements in mRNA production and development programs.
TriLink's introduction of CleanCap M6, its most robust CleanCap analog to date, has demonstrated increased mRNA expression by over 30% compared to enzymatic capping methods, suggesting improved performance and efficacy in mRNA applications.
Negative
While the agreement with Lonza enhances the accessibility of CleanCap technology, it is non-exclusive, potentially leading to competition from other providers offering similar mRNA capping solutions in the market.
Although CleanCap technology has been successful in advancing the mRNA capping industry and is used in approved vaccines, there may be challenges in maintaining a competitive edge as other technologies emerge in the field.
Lonza customers can now access TriLink’s CleanCap® mRNA capping technology for non-commercial use, enabling further development of critical mRNA therapeutics
SAN DIEGO--(BUSINESS WIRE)--
TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.
According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.
“CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”
Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit maravai.com.
What is the agreement between TriLink BioTechnologies and Lonza?
TriLink BioTechnologies and Lonza have entered into a non-exclusive License and Supply Agreement for TriLink's CleanCap mRNA capping technology.
What benefits does CleanCap technology offer?
CleanCap technology provides high capping efficiency, streamlines mRNA production processes, improves mRNA function, and increases capped material yield.
What is CleanCap M6?
CleanCap M6 is TriLink's latest CleanCap analog, showing over 30% increased mRNA expression compared to enzymatic capping methods.
maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri
